Base de dados : MEDLINE Pesquisa : D02.092.705.800 [Categoria DeCS] Referências encontradas : 2723 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 273

ir para página

1 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27770542 [Au] Autor: Shen ZQ; Gao SY; Li SX; Zhang TN; Liu CX; Lv HC; Zhang Y; Gong TT; Xu X; Ji C; Wu QJ; Li D [Ad] Endereço: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China. [Ti] Título: Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. [So] Source: Br J Clin Pharmacol;83(4):909-922, 2017 04. [Is] ISSN: 1365-2125 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: AIM: To perform a meta-analysis of available cohort studies on the association between sertraline use by pregnant women in the first trimester and the findings of congenital anomalies in infants. METHODS: A comprehensive search of articles published from the index date up to 31 December 2015 investigating the aforementioned associations was conducted on PubMed and Web of Science. Mesh headings used included the terms "serotonin reuptake inhibitor," "sertraline," "congenital anomalies" and "obstetrical outcome." RESULTS: Twelve cohort studies that involved 6 468 241 pregnant women were identified. We summarized odds ratios (ORs) and 95% confidence intervals (CIs) of congenital anomalies using the random-effects model. Pregnant women who used sertraline in the first trimester had a statistically significant increased risk of infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I  = 64.4%; n = 12) as well as atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I  = 62.2%; n = 8). Additionally, positive but nonsignificant associations between sertraline use and congenital anomalies of the nervous system (OR = 1.39; 95% CI = 0.83-2.32; I  = 0%; n = 5), digestive system (OR = 1.23; 95% CI = 0.76-1.98; I  = 0%; n = 5), eye, ear, face and neck (OR = 1.08; 95% CI = 0.33-3.55; I  = 32.1%; n = 3), urogenital system (OR = 1.03; 95% CI = 0.73-1.46; I  = 0%; n = 5), and musculoskeletal system (OR = 0.97; 95% CI = 0.69-1.36; I  = 0%; n = 5) were observed. CONCLUSION: This meta-analysis suggested that the use of sertraline use by pregnant women in the first trimester had an increased risk of cardiovascular-related malformations as well as atrial and/or ventricular septal defects in infants. Meanwhile, nonsignificant associations between sertraline use and other congenital anomalies were found. More cohort studies are warranted to provide detailed results of other congenital anomalies. [Mh] Termos MeSH primário: Anormalidades Induzidas por Medicamentos/etiologia Inibidores da Captação de Serotonina/administração & dosagem Sertralina/administração & dosagem [Mh] Termos MeSH secundário: Anormalidades Induzidas por Medicamentos/epidemiologia Estudos de Coortes Feminino Seres Humanos Lactente Gravidez Primeiro Trimestre da Gravidez Risco Inibidores da Captação de Serotonina/efeitos adversos Sertralina/efeitos adversos [Pt] Tipo de publicação: JOURNAL ARTICLE; META-ANALYSIS; REVIEW; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Serotonin Uptake Inhibitors); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 180228 [Lr] Data última revisão: 180228 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 161023 [St] Status: MEDLINE [do] DOI: 10.1111/bcp.13161

2 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 29173738 [Au] Autor: Peris TS; Caporino NE; O'Rourke S; Kendall PC; Walkup JT; Albano AM; Bergman RL; McCracken JT; Birmaher B; Ginsburg GS; Sakolsky D; Piacentini J; Compton SN [Ad] Endereço: UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA. Electronic address: tperis@mednet.ucla.edu. [Ti] Título: Therapist-Reported Features of Exposure Tasks That Predict Differential Treatment Outcomes for Youth With Anxiety. [So] Source: J Am Acad Child Adolesc Psychiatry;56(12):1043-1052, 2017 Dec. [Is] ISSN: 1527-5418 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: OBJECTIVE: Exposure tasks are recognized widely as a key component of cognitive-behavioral therapy (CBT) for child and adolescent anxiety. However, little research has examined specific exposure characteristics that predict outcomes for youth with anxiety and that may guide its application in therapy. METHOD: This study draws on a sample of 279 children and adolescents (48.4% male; 79.6% white) with a principal anxiety disorder who received 14 sessions of CBT, either alone or in combination with medication, through the Child/adolescent Anxiety Multimodal treatment Study (CAMS). The present study examines therapist-reported quantity, difficulty level, compliance, and mastery of exposure tasks as they related to CBT response (i.e., Clinical Global Impressions-Improvement ratings). Secondary treatment outcomes included reduction in anxiety symptom severity on the Pediatric Anxiety Rating Scale, global impairment measured via the Children's Global Assessment Scale, and parent-report of anxiety-specific functional impairment on the Child Anxiety Impairment Scale. RESULTS: Regression analyses indicated a dose-response relationship between therapist-reported quantity of exposure and independent evaluations of treatment outcome, with more time devoted to exposure linked to better outcomes. Similarly, greater time spent on more difficult (rather than mild or moderate) exposure tasks predicted better outcomes, as did therapist ratings of child compliance and mastery. CONCLUSION: The present findings highlight the importance of challenging children and adolescents with difficult exposure tasks and of collaborating to ensure compliance and mastery. [Mh] Termos MeSH primário: Transtornos de Ansiedade/terapia Terapia Cognitiva/métodos [Mh] Termos MeSH secundário: Adolescente Ansiolíticos/uso terapêutico Transtornos de Ansiedade/psicologia Criança Terapia Combinada Feminino Seres Humanos Masculino Sertralina/uso terapêutico Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL [Nm] Nome de substância: 0 (Anti-Anxiety Agents); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1802 [Cu] Atualização por classe: 180202 [Lr] Data última revisão: 180202 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171128 [St] Status: MEDLINE

3 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28459660 [Au] Autor: Firouzabadi N; Raeesi R; Zomorrodian K; Bahramali E; Yavarian I [Ad] Endereço: Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. Non communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. Yasuj University of Medical Sciences, Yasuj, Iran. [Ti] Título: Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients. [So] Source: J Pharm Pharm Sci;20:1-7, 2017. [Is] ISSN: 1482-1826 [Cp] País de publicação: Canada [La] Idioma: eng [Ab] Resumo: PURPOSE: The adrenoceptor family, as one of the main contributors in regulating the noradrenergic system, has been studied in involvement of depression and its treatment. A functional polymorphism of G1165C on beta adrenoceptor (ßAR) enhances post receptor signalling and is assumed to be involved in pharmacotherapy of depression. The aim of the present study was to discern the influence of G1165C polymorphism in the ß1AR gene on individual differences in response to sertraline. METHODS: One hundred newly diagnosed patients completed 6 weeks of sertraline treatment. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for depression (HRSD). RESULTS: The patients who carried CC genotype responded five times more to sertraline comparing with other variants (P=0.005; OR=5.7; 95%CI=1.4-23.9). Moreover, carriers of C allele responded three times more to sertraline than patients with the G allele (P=0.001; OR= 3.3; 95%CI= 1.72-6.50). CONCLUSION: In conclusion, our results support the hypothesis that genetic variation of ß1AR might influence clinical response to sertraline. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page. [Mh] Termos MeSH primário: Antidepressivos/uso terapêutico Transtorno Depressivo Maior/tratamento farmacológico Polimorfismo Genético/genética Receptores Adrenérgicos/genética Sertralina/uso terapêutico [Mh] Termos MeSH secundário: Adulto Antidepressivos/administração & dosagem Transtorno Depressivo Maior/diagnóstico Transtorno Depressivo Maior/genética Feminino Genótipo Seres Humanos Masculino Receptores Adrenérgicos/metabolismo Sertralina/administração & dosagem [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antidepressive Agents); 0 (Receptors, Adrenergic); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1712 [Cu] Atualização por classe: 171222 [Lr] Data última revisão: 171222 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170502 [St] Status: MEDLINE [do] DOI: 10.18433/J3W31F

4 / 2723

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 29202148 [Au] Autor: Berko EH; Feier G [Ad] Endereço: Case Western Reserve University School of Medicine, Cleveland, OH, USA. Email: eberko@metrohealth.org. [Ti] Título: Behavioral Health Consult: Ensuring prompt recognition and treatment of panic disorder. [So] Source: J Fam Pract;66(12):750-753, 2017 Dec. [Is] ISSN: 1533-7294 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Lorna D was seen by her primary care physician as follow-up to a visit she made to the emergency department (ED). The 37 year old had gone to the ED 4 times in the previous year. Each time she presented with tachycardia, dyspnea, nausea, numbness in her extremities, and a fear that she was having a heart attack. In spite of negative work-ups at each visit (electrocardiogram, cardiac enzymes, complete blood count, toxicology screen, Holter monitoring), Ms. D was terrified that the ED doctors were missing something. She was still "rattled" by the chest pain and shortness of breath she had experienced. Mild symptoms were persisting and she was worried that she would have a heart attack and die without the treatment she believed she needed. How would you proceed with this patient? [Mh] Termos MeSH primário: Antidepressivos/uso terapêutico Terapia Cognitiva Transtorno de Pânico/diagnóstico Transtorno de Pânico/terapia Sertralina/uso terapêutico [Mh] Termos MeSH secundário: Adulto Algoritmos Terapia Combinada Diagnóstico Diferencial Feminino Seres Humanos Prognóstico [Pt] Tipo de publicação: CASE REPORTS [Nm] Nome de substância: 0 (Antidepressive Agents); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1712 [Cu] Atualização por classe: 171208 [Lr] Data última revisão: 171208 [Sb] Subgrupo de revista: AIM; IM [Da] Data de entrada para processamento: 171205 [St] Status: MEDLINE

5 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 29020098 [Au] Autor: Kromann S; Kudirkiene E; Li L; Thoefner I; Daldorph E; Christensen JP; Meng H; Olsen RH [Ad] Endereço: Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark. [Ti] Título: Treatment with high-dose antidepressants severely exacerbates the pathological outcome of experimental Escherichia coli infections in poultry. [So] Source: PLoS One;12(10):e0185914, 2017. [Is] ISSN: 1932-6203 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: There is an urgent need for novel antibiotics as the current antibiotics are losing their value due to increased resistance among clinically important bacteria. Sertraline, an on-marked anti-depressive drug, has been shown to modify bacterial activity in vitro, including increasing the susceptibility of Escherichia coli to antibiotics. The aim of the present study was to investigate if the antimicrobial activity of sertraline could be documented under clinical settings, hereunder if sertraline could potentiate the effect of tetracycline in treatment of an experimentally induced ascending infection in poultry. A total of 40 chickens were divided in four groups of 10 chickens each. All chickens were challenged with 4x103 colony forming units (CFU) of a tetracycline resistant E. coli strain using a surgical infection model, and subsequently treated with either high-dose sertraline, tetracycline, a combination hereof or received no treatment. Seven days post challenge all birds were submitted to necropsy and scored pathologically for lesions. The average lesion scores were significantly higher (P<0.05) in the groups that were treated with high-dose sertraline or high-dose sertraline combined with tetracycline. In conclusion high-dose treatments (four times the maximum therapeutic dose for treating human depression) with sertraline as an adjuvant for treatment of antibiotic resistant E. coli infections exacerbate the pathological outcome of infection in chickens. [Mh] Termos MeSH primário: Antidepressivos/uso terapêutico Galinhas/microbiologia Progressão da Doença Infecções por Escherichia coli/tratamento farmacológico Infecções por Escherichia coli/microbiologia Escherichia coli/fisiologia Doenças das Aves Domésticas/tratamento farmacológico Doenças das Aves Domésticas/microbiologia [Mh] Termos MeSH secundário: Animais Antidepressivos/farmacologia Peso Corporal/efeitos dos fármacos Contagem de Colônia Microbiana Relação Dose-Resposta a Droga Sinergismo Farmacológico Escherichia coli/efeitos dos fármacos Escherichia coli/crescimento & desenvolvimento Tubas Uterinas/efeitos dos fármacos Tubas Uterinas/microbiologia Feminino Imuno-Histoquímica Fígado/patologia Sertralina/farmacologia Sertralina/uso terapêutico Tetraciclina/farmacologia Tetraciclina/uso terapêutico [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antidepressive Agents); F8VB5M810T (Tetracycline); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1710 [Cu] Atualização por classe: 171031 [Lr] Data última revisão: 171031 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171012 [St] Status: MEDLINE [do] DOI: 10.1371/journal.pone.0185914

6 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28844482 [Au] Autor: Vichier-Guerre C; Parker M; Pomerantz Y; Finnell RH; Cabrera RM [Ad] Endereço: Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX 78712, United States. [Ti] Título: Impact of selective serotonin reuptake inhibitors on neural crest stem cell formation. [So] Source: Toxicol Lett;281:20-25, 2017 Nov 05. [Is] ISSN: 1879-3169 [Cp] País de publicação: Netherlands [La] Idioma: eng [Ab] Resumo: The use of antidepressants in pregnant women is rising, with rates up to 7.5% in the United States. Selective serotonin reuptake inhibitors (SSRIs) are currently the most common antidepressant prescribed to pregnant women. The teratogenic effects of SSRI exposure are debated because of discrepancies in epidemiological studies. As an alternative to epidemiological and animal studies, human embryonic stem cell research (hESC) provides a human-based experimental model to examine the risks of prenatal SSRI exposure. Neural crest stem cells (NCSCs) play an important role in craniofacial and cardiac development as precursors to craniofacial bones and heart septa. This study examines the effects of paroxetine (Paxil) and sertraline (Zoloft) exposure on proliferation, migration, and AP-2α protein expression of NCSC in vitro. hESCs were exposed to paroxetine and sertraline at three concentrations while undergoing directed differentiation into NCSCs. Our results indicate exposure to paroxetine significantly increased proliferation, migration, and AP-2α protein expression in NCSCs. Exposure to sertraline significantly decreased proliferation and significantly increased AP-2α protein expression in NCSC. This evidence suggests paroxetine and sertraline alter normal NCSC behavior and may thereby disrupt cardiac and craniofacial development. [Mh] Termos MeSH primário: Antidepressivos/toxicidade Células-Tronco Embrionárias/efeitos dos fármacos Crista Neural/efeitos dos fármacos Inibidores da Captação de Serotonina/toxicidade [Mh] Termos MeSH secundário: Linhagem Celular Movimento Celular/efeitos dos fármacos Proliferação Celular/efeitos dos fármacos Células-Tronco Embrionárias/citologia Regulação da Expressão Gênica Seres Humanos Crista Neural/citologia Paroxetina/toxicidade Sertralina/toxicidade Fator de Transcrição AP-2/genética Fator de Transcrição AP-2/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antidepressive Agents); 0 (Serotonin Uptake Inhibitors); 0 (Transcription Factor AP-2); 41VRH5220H (Paroxetine); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 171106 [Lr] Data última revisão: 171106 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170829 [St] Status: MEDLINE

7 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28751755 [Au] Autor: Boia-Ferreira M; Basílio AB; Hamasaki AE; Matsubara FH; Appel MH; Da Costa CRV; Amson R; Telerman A; Chaim OM; Veiga SS; Senff-Ribeiro A [Ad] Endereço: Department of Cell Biology, Centro Politécnico, Federal University of Paraná, UFPR, Jardim das Américas, CEP 81531-990, Curitiba, Paraná, Brazil. [Ti] Título: TCTP as a therapeutic target in melanoma treatment. [So] Source: Br J Cancer;117(5):656-665, 2017 Aug 22. [Is] ISSN: 1532-1827 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: BACKGROUND: Translationally controlled tumour protein (TCTP) is an antiapoptotic protein highly conserved through phylogeny. Translationally controlled tumour protein overexpression was detected in several tumour types. Silencing TCTP was shown to induce tumour reversion. There is a reciprocal repression between TCTP and P53. Sertraline interacts with TCTP and decreases its cellular levels. METHODS: We evaluate the role of TCTP in melanoma using sertraline and siRNA. Cell viability, migration, and clonogenicity were assessed in human and murine melanoma cells in vitro. Sertraline was evaluated in a murine melanoma model and was compared with dacarbazine, a major chemotherapeutic agent used in melanoma treatment. RESULTS: Inhibition of TCTP levels decreases melanoma cell viability, migration, clonogenicity, and in vivo tumour growth. Human melanoma cells treated with sertraline show diminished migration properties and capacity to form colonies. Sertraline was effective in inhibiting tumour growth in a murine melanoma model; its effect was stronger when compared with dacarbazine. CONCLUSIONS: Altogether, these results indicate that sertraline could be effective against melanoma and TCTP can be a target for melanoma therapy. [Mh] Termos MeSH primário: Biomarcadores Tumorais/antagonistas & inibidores Biomarcadores Tumorais/genética Melanoma/genética RNA Mensageiro/metabolismo Sertralina/farmacologia Neoplasias Cutâneas/tratamento farmacológico [Mh] Termos MeSH secundário: Animais Antineoplásicos Alquilantes/uso terapêutico Biomarcadores Tumorais/metabolismo Linhagem Celular Tumoral Movimento Celular/efeitos dos fármacos Proliferação Celular/genética Sobrevivência Celular/efeitos dos fármacos Dacarbazina/uso terapêutico Feminino Expressão Gênica/efeitos dos fármacos Expressão Gênica/genética Inativação Gênica Seres Humanos Melanoma/metabolismo Melanoma Experimental/tratamento farmacológico Camundongos Camundongos Endogâmicos C57BL RNA Interferente Pequeno/genética Sertralina/uso terapêutico Transfecção Ensaio Tumoral de Célula-Tronco Proteína Supressora de Tumor p53/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antineoplastic Agents, Alkylating); 0 (Biomarkers, Tumor); 0 (RNA, Messenger); 0 (RNA, Small Interfering); 0 (Tumor Suppressor Protein p53); 0 (tumor protein, translationally-controlled 1); 7GR28W0FJI (Dacarbazine); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170918 [Lr] Data última revisão: 170918 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170729 [St] Status: MEDLINE [do] DOI: 10.1038/bjc.2017.230

8 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28698674 [Au] Autor: Li L; Kromann S; Olsen JE; Svenningsen SW; Olsen RH [Ad] Endereço: College of Light Industry and Food Sciences, South China University of Technology, Frederiksberg C, Denmark. [Ti] Título: Insight into synergetic mechanisms of tetracycline and the selective serotonin reuptake inhibitor, sertraline, in a tetracycline-resistant strain of Escherichia coli. [So] Source: J Antibiot (Tokyo);70(9):944-953, 2017 Aug. [Is] ISSN: 0021-8820 [Cp] País de publicação: Japan [La] Idioma: eng [Ab] Resumo: Sertraline, an antidepressive drug, has been reported to inhibit general bacterial efflux pumps. In the present study, we report for the first time a synergistic effect of sertraline and tetracycline in a TetA-encoded tetracycline-resistant strain of Escherichia coli. Synergy between sertraline and tetracycline in an E. coli strain with TetA-mediated tetracycline resistance (E. coli APEC_O2) was assessed by the MIC and checkerboard assays. The global transcriptome of E. coli APEC_O2 exposed to ½ MIC concentrations of sertraline and/or tetracycline was analyzed to elucidate the interaction mechanism between sertraline and tetracycline. The fractional inhibitory concentration index for tetracycline and sertraline in E. coli APEC_O2 was 0.5. In addition, in the presence of ½ MIC of sertraline, the sensitivity of E. coli APEC_O2 to tetracycline could be restored according to clinical standards (from 64 to 4 mg l ). RNA data suggest changes in respiration that is likely to decrease intracellular pH and thereby the proton-motive force, which provides the energy for the tetracycline efflux pump. Furthermore, sertraline and tetracycline may induce a change from oxidation to fermentation in the E.coli, which further decreases pH, resulting in cell death. This study shows that sertraline interacts with tetracycline in a synergistic and AcrAB-TolC pump-independent manner. The combinational treatment was further shown to induce many changes in the global transcriptome, including altered tetA and tetR expression. The results indicate that sertraline may be used as a helper compound with the aim to reverse tetracycline resistance encoded by tetA. [Mh] Termos MeSH primário: Antibacterianos/farmacologia Antidepressivos/farmacologia Escherichia coli/efeitos dos fármacos Inibidores da Captação de Serotonina/farmacologia Sertralina/farmacologia Resistência a Tetraciclina Tetraciclina/farmacologia [Mh] Termos MeSH secundário: Antibacterianos/química Antidepressivos/química Biologia Computacional Sinergismo Farmacológico Transporte de Elétrons/efeitos dos fármacos Complexo de Proteínas da Cadeia de Transporte de Elétrons/genética Complexo de Proteínas da Cadeia de Transporte de Elétrons/metabolismo Escherichia coli/crescimento & desenvolvimento Proteínas de Escherichia coli/genética Proteínas de Escherichia coli/metabolismo Fermentação/efeitos dos fármacos Perfilação da Expressão Gênica Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos Concentração de Íons de Hidrogênio Concentração Inibidora 50 Líquido Intracelular/efeitos dos fármacos Líquido Intracelular/metabolismo Testes de Sensibilidade Microbiana Viabilidade Microbiana/efeitos dos fármacos Oxirredução Força Próton-Motriz/efeitos dos fármacos Inibidores da Captação de Serotonina/agonistas Sertralina/agonistas Tetraciclina/agonistas [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 0 (Antidepressive Agents); 0 (Electron Transport Chain Complex Proteins); 0 (Escherichia coli Proteins); 0 (Serotonin Uptake Inhibitors); F8VB5M810T (Tetracycline); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170913 [Lr] Data última revisão: 170913 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170713 [St] Status: MEDLINE [do] DOI: 10.1038/ja.2017.78

9 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28386654 [Au] Autor: Carty DR; Hala D; Huggett DB [Ad] Endereço: Department of Biology, Institute of Applied Sciences, University of North Texas, 1704 West Mulberry Room 215, Denton, TX, 76201, USA. dcarty@go.olemiss.edu. [Ti] Título: The Effects of Sertraline on Fathead Minnow (Pimephales promelas) Growth and Steroidogenesis. [So] Source: Bull Environ Contam Toxicol;98(6):753-757, 2017 Jun. [Is] ISSN: 1432-0800 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The purpose of this study was to evaluate the steroidogenic effects of sertraline, a popular selective serotonin reuptake inhibitor, on larval fathead minnow (FHM; Pimephales promelas) and adult FHM. Larvae were exposed to 0.1, 1, and 10 µg/L sertraline for 28 days and analyzed for differential mRNA expression of 11ß-hydroxysteroid dehydrogenase (11ß-HSD), 20ß-hydroxysteroid dehydrogenase (20ß-HSD), aromatase (CYP19a), nuclear thyroid receptor alpha (TRα), and normalized to RP-L8. Adult FHM were exposed to 3 or 10 µg/L sertraline for 7 days and analyzed for differential expression of the same genes with the addition of thyroid receptor beta (TRß). Larval FHM exposed to 0.1 µg/L had a significant upregulation of both 20ß-HSD and TRα while adult FHM exposed to 10 µg/L had a significant upregulation of 11ß-HSD expression in brain tissue. The significance of these findings with respect to survival, growth and reproduction are currently unknown, but represent areas for future research. [Mh] Termos MeSH primário: Cyprinidae/fisiologia Sertralina/toxicidade Esteroides/metabolismo Poluentes Químicos da Água/toxicidade [Mh] Termos MeSH secundário: Animais Aromatase Cyprinidae/metabolismo Feminino Masculino Reprodução/efeitos dos fármacos Poluentes Químicos da Água/metabolismo [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Steroids); 0 (Water Pollutants, Chemical); EC 1.14.14.1 (Aromatase); EC 1.14.14.1 (CYP19A1 protein, human); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1707 [Cu] Atualização por classe: 170719 [Lr] Data última revisão: 170719 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170408 [St] Status: MEDLINE [do] DOI: 10.1007/s00128-017-2079-5

10 / 2723

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28343407 [Au] Autor: Jones M; Acion L; Jorge RE [Ad] Endereço: a VA South Central Mental Illness Research , Education and Clinical Center , Houston , TX , USA. [Ti] Título: What are the complications and emerging strategies for preventing depression following traumatic brain injury? [So] Source: Expert Rev Neurother;17(6):631-640, 2017 Jun. [Is] ISSN: 1744-8360 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: INTRODUCTION: Depression is a common and disabling complication of traumatic brain injury (TBI). The high rates of post-TBI depression (PTBID) make this condition an important candidate for selective preventive interventions. Areas covered: The authors recently reported on the efficacy of sertraline, a selective serotonin reuptake inhibitor (SSRI), for the prevention of new cases of depression in the first six months after TBI. The authors review this and other studies on preventive strategies in PTBID as ascertained from a PubMed and citation search. The potential complications and barriers to the implementation of pharmacological prevention in patients with TBI are also discussed. Expert commentary: The prevention of depression in patients with TBI has received little attention relative to other medical conditions. Future studies are needed to confirm the benefit of SSRIs and investigate other pharmacological and non-pharmacological interventions, including in special groups of patients at greater risk of developing PTBID. [Mh] Termos MeSH primário: Lesões Encefálicas Traumáticas/complicações Depressão [Mh] Termos MeSH secundário: Depressão/tratamento farmacológico Depressão/etiologia Depressão/prevenção & controle Seres Humanos Inibidores da Captação de Serotonina/uso terapêutico Sertralina/uso terapêutico [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Serotonin Uptake Inhibitors); QUC7NX6WMB (Sertraline) [Em] Mês de entrada: 1707 [Cu] Atualização por classe: 170726 [Lr] Data última revisão: 170726 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170328 [St] Status: MEDLINE [do] DOI: 10.1080/14737175.2017.1311788

---

página 1 de 273

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde